Grace Therapeutics, Inc. (GRCE)
Nasdaq · Healthcare · Biotechnology
$2.06−0.48%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $43.3M
- 52-week range
- $1.79 – $5.18
- 52-week change
- −31.46%
- EPS (trailing)
- −$1.17
Fiscal year to Mar 2026
- Net income
- −$7.8M
- Diluted EPS
- −$0.47
From the company’s annual report on SEC EDGAR.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Headquarters: Princeton, United States · 5 employees · gracetx.com